Published in World J Gastroenterol on May 14, 2014
Factors Associated With Protein-energy Malnutrition in Chronic Liver Disease: Analysis Using Indirect Calorimetry. Medicine (Baltimore) (2016) 0.85
Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis. Dig Dis Sci (2016) 0.79
Effective Prevention of Liver Fibrosis by Liver-targeted Hydrodynamic Gene Delivery of Matrix Metalloproteinase-13 in a Rat Liver Fibrosis Model. Mol Ther Nucleic Acids (2016) 0.78
Serum hyaluronic acid predicts protein-energy malnutrition in chronic hepatitis C. Medicine (Baltimore) (2016) 0.77
Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C. J Clin Transl Hepatol (2014) 0.76
Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs. J Vet Sci (2016) 0.75
Outcomes of abdominal surgery in patients with liver cirrhosis. World J Gastroenterol (2016) 0.75
Malnutrition negatively impacts the quality of life of patients with cirrhosis: An observational study. World J Hepatol (2017) 0.75
Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure. World J Gastroenterol (2015) 0.75
Effects of Fibrotic Tissue on Liver-targeted Hydrodynamic Gene Delivery. Mol Ther Nucleic Acids (2016) 0.75
Polyethylene Glycol and Lactulose versus Lactulose Alone in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis: A Non-Inferiority Randomized Controlled Trial. Middle East J Dig Dis (2017) 0.75
Changing common sense: Anti-platelet/coagulation therapy against cirrhosis. World J Hepatol (2015) 0.75
Cirrhosis of liver: Interference of serpins in quantification of SERPINA4 - A preliminary study. Pract Lab Med (2017) 0.75
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
Estimating the world cancer burden: Globocan 2000. Int J Cancer (2001) 16.92
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med (2006) 10.63
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA (2013) 10.43
Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med (2013) 10.19
A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology (2000) 9.74
Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology (2002) 7.53
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med (1999) 5.89
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology (2012) 5.75
Management of adult patients with ascites due to cirrhosis: an update. Hepatology (2009) 5.26
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA (2010) 4.71
Hepatopulmonary syndrome--a liver-induced lung vascular disorder. N Engl J Med (2008) 4.71
The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med (2010) 4.64
Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol (2012) 4.62
Care of patients with ascites. N Engl J Med (1994) 4.46
Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol (2001) 4.46
Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology (2007) 4.35
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA (2013) 3.82
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology (2007) 3.73
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71
Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol (2005) 3.68
Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med (1988) 3.53
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology (1993) 3.28
Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med (2004) 3.24
Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology (2003) 3.19
A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology (2003) 3.09
Compensated cirrhosis: natural history and prognostic factors. Hepatology (1987) 3.01
Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology (1990) 2.99
Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med (2001) 2.95
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology (2002) 2.93
Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology (2004) 2.91
Chemoembolization for hepatocellular carcinoma. Gastroenterology (2004) 2.89
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology (2008) 2.89
Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastroenterology (1989) 2.88
The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med (2008) 2.85
Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J (2004) 2.80
Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis. Gastroenterology (1990) 2.78
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology (2004) 2.77
Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis (2001) 2.76
A prospective study of bacterial infections in patients with cirrhosis. J Hepatol (1993) 2.75
Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol (1999) 2.70
A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology (2001) 2.64
Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol (2011) 2.59
Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology (2009) 2.59
Bacterial infection in cirrhotic patients and its relationship with alcohol. Am J Gastroenterol (2000) 2.55
Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology (2002) 2.49
Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis (2008) 2.47
Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol (2003) 2.46
Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med (2000) 2.43
Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology (2003) 2.38
Hepatic Encephalopathy. Am J Gastroenterol (2001) 2.37
The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology (2004) 2.36
Management of patients with cirrhosis awaiting liver transplantation. Gut (2010) 2.34
A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices. Am J Gastroenterol (2002) 2.32
Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med (1992) 2.31
The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology (2005) 2.28
A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med (2000) 2.20
Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol (1994) 2.20
Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology (1999) 2.18
A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol (2005) 2.15
Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis (1999) 2.15
Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology (1991) 2.12
Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology (1998) 2.10
Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther (2009) 2.09
Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet (1984) 2.09
Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology (2005) 2.05
Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol (2004) 2.04
Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology (1996) 2.00
Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol (2004) 1.97
A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology (2007) 1.96
Risk factors for the presence of varices in cirrhotic patients without a history of variceal hemorrhage. Arch Intern Med (2001) 1.96
Electrolyte studies on patients with cirrhosis of the liver. J Clin Invest (1950) 1.94
Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut (2005) 1.93
Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology (2012) 1.92
Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology (2001) 1.91
The North American Study for the Treatment of Refractory Ascites. Gastroenterology (2003) 1.87
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol (2007) 1.87
A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol (2009) 1.86
The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology (2007) 1.86
Recovery from "hepatorenal syndrome" after orthotopic liver transplantation. N Engl J Med (1973) 1.85
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer (2007) 1.83
Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology (2010) 1.77
Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology (1999) 1.74
A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol (2005) 1.73
Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology (1984) 1.73
Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med (1992) 1.72
Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med (2009) 1.72
Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology (2004) 1.71
Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and analytical characteristics, diagnosis and management. J Hepatol (2009) 1.71
Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology (2008) 1.70
Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. Gut (2010) 1.65
Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ (2004) 1.64
Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology (1999) 1.64
Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology (1990) 1.63